Misti Zotz
Psychiatric/Mental Health · Paradise, TXNPI 1063142156
Payments from drug & device makers
Across 77 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$564
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$132
- Corium, LLC$109
- Lundbeck LLC$102
- Axsome Therapeutics, Inc.$100
- Johnson & Johnson$84
- plus $293 from 10 others
What the payments were for
- Food & beverage$1,384100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $564 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $132 |
| Corium, LLC | 6 | $109 |
| Lundbeck LLC | 6 | $102 |
| Axsome Therapeutics, Inc. | 5 | $100 |
| Johnson & Johnson | 5 | $84 |
| Tris Pharma Inc | 3 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $52 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Neurocrine Biosciences, Inc. | 1 | $37 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| GE HealthCare | 1 | $16 |
| Indivior Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Biogen | 1 | $14 |
How this compares
$1,384 in reported general payments places this provider in the 65th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyzine Hcl | 34 | $532 |
| Vilazodone Hcl | 12 | $503 |
| Bupropion XlBupropion Hcl | 34 | $486 |
| Quetiapine Fumarate | 45 | $337 |
| Duloxetine Hcl | 34 | $334 |
| Clonazepam | 31 | $327 |
| Buspirone Hcl | 13 | $239 |
| Temazepam | 14 | $224 |
| Gabapentin | 14 | $218 |
| Mirtazapine | 17 | $205 |
| Sertraline Hcl | 108 | $196 |
| Zolpidem Tartrate | 15 | $178 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 11 | $177 |
| Oxcarbazepine | 11 | $160 |
| Lorazepam | 34 | $151 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Paradise
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
- Jaime Nelson DensonAustin$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.